Sullivan & Cromwell is seeing double on the billion-dollar deal front this week.
Following a judge’s ruling that Kirkland & Ellis should not move forward on representing Teva Pharmaceutical Industries Ltd. in its $40 billion unsolicited bid for Mylan NV, Sullivan & Cromwell was beckoned by the would-be acquirer to step in for its previous counsel. The switch-up—which stems Kirkland’s prior work for various Mylan entities, potentially giving the firm access to confidential company information—will see Kirkland object to the potential change.
